These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36041429)

  • 1. Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
    You R; Zou X; Ding X; Zhang WJ; Zhang MX; Wang X; Xu HS; Liu YL; Ouyang YF; Duan CY; Gu CM; Wang ZQ; Liu YP; Hua YJ; Huang PY; Chen MY
    Med; 2022 Oct; 3(10):664-681.e6. PubMed ID: 36041429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
    Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi Y; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Wang S; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Luo X; Wang X; Tang X; Feng H; Yao S; Keegan P; Xu RH
    JAMA; 2023 Nov; 330(20):1961-1970. PubMed ID: 38015220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
    Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
    Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi YR; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Liu Z; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Feng H; Yao S; Keegan P; Xu RH
    Nat Med; 2021 Sep; 27(9):1536-1543. PubMed ID: 34341578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
    Liu X; Zhang Y; Yang KY; Zhang N; Jin F; Zou GR; Zhu XD; Xie FY; Liang XY; Li WF; He ZY; Chen NY; Hu WH; Wu HJ; Shi M; Zhou GQ; Mao YP; Guo R; Sun R; Huang J; Liang SQ; Wu WL; Su Z; Li L; Ai P; He YX; Zang J; Chen L; Lin L; Huang SH; Xu C; Lv JW; Li YQ; Hong SB; Jie YS; Li H; Huang SW; Liang YL; Wang YQ; Peng YL; Zhu JH; Zang SB; Liu SR; Lin QG; Li HJ; Tian L; Liu LZ; Zhao HY; Lin AH; Li JB; Liu N; Tang LL; Chen YP; Sun Y; Ma J
    Lancet; 2024 Jun; 403(10445):2720-2731. PubMed ID: 38824941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
    Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
    Zhang L; Huang Y; Hong S; Yang Y; Yu G; Jia J; Peng P; Wu X; Lin Q; Xi X; Peng J; Xu M; Chen D; Lu X; Wang R; Cao X; Chen X; Lin Z; Xiong J; Lin Q; Xie C; Li Z; Pan J; Li J; Wu S; Lian Y; Yang Q; Zhao C
    Lancet; 2016 Oct; 388(10054):1883-1892. PubMed ID: 27567279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
    Abraham I; Calamia M; Alkhatib N; Pondel M; MacDonald K
    J Med Econ; 2024; 27(sup3):9-23. PubMed ID: 39016811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.
    Zou X; Ding X; Feng ZK; Ouyang YF; Li HF; Wen K; Wang ZQ; Liu YP; Liu YL; Zhang WJ; Yang Q; Chen SY; Xie YL; Xie RQ; Lin C; Gu CM; Huang PY; Sun R; Hua YJ; You R; Chen MY
    Cell Rep Med; 2024 Oct; 5(10):101779. PubMed ID: 39413735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-efficiency and budget-neutral expanded access modeling of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.
    MacDonald K; Pondel M; Abraham I
    J Med Econ; 2024; 27(sup3):1-8. PubMed ID: 38488887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.
    Mo Y; Pan Y; Zhang B; Zhang J; Su Y; Liu Z; Luo M; Qin G; Kong X; Zhang R; Pan Y; Liang Y; Wang D; Wei Y; Chen H; Jiang W
    Front Immunol; 2023; 14():1298418. PubMed ID: 38239359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
    Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
    Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
    Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
    J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
    Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
    You R; Liu YP; Xie YL; Lin C; Duan CY; Chen DP; Pan Y; Qi B; Zou X; Guo L; Cao JY; Zhang YN; Wang ZQ; Liu YL; Ouyang YF; Wen K; Yang Q; Xie RQ; Li HF; Duan XT; Ding X; Peng L; Chen SY; Liang JL; Feng ZK; Xia TL; Xie RL; Jiang R; Gu CM; Liu RZ; Sun R; Yang X; Liu LZ; Ling L; Liu Q; Ng WT; Hua YJ; Huang PY; Chen MY
    Lancet; 2023 Mar; 401(10380):917-927. PubMed ID: 36842439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.
    Yang R; Li R; Niu X; Zhao Y; Yan L; Tian S; Zhu Y; Qiu J; Wang X
    Oral Oncol; 2024 Nov; 158():106981. PubMed ID: 39142147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
    Jung HA; Park KU; Cho S; Lim J; Lee KW; Hong MH; Yun T; An HJ; Park WY; Pereira S; Ock CY; Keam B
    Clin Cancer Res; 2022 Oct; 28(19):4240-4247. PubMed ID: 35819451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
    Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
    BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study.
    Lu N; Jiang YF; Xia WX; Huang Y; Xie CM; Xu C; Ye YF; Liu GY; Bei WX; Ke LR; Li WZ; Zhang C; Wang X; Liu Q; Chen X; Chen ZX; Xie C; Liang H; Xiang YQ
    EClinicalMedicine; 2023 Aug; 62():102136. PubMed ID: 37593221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.
    Yang Y; Qu S; Li J; Hu C; Xu M; Li W; Zhou T; Shen L; Wu H; Lang J; Hu G; Luo Z; Fu Z; Qu S; Feng W; Chen X; Lin S; Zhang W; Li X; Sun Y; Lin Z; Lin Q; Lei F; Long J; Hong J; Huang X; Zeng L; Wang P; He X; Zhang B; Yang Q; Zhang X; Zou J; Fang W; Zhang L
    Lancet Oncol; 2021 Aug; 22(8):1162-1174. PubMed ID: 34174189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.